JP2025525098A5 - - Google Patents

Info

Publication number
JP2025525098A5
JP2025525098A5 JP2025505402A JP2025505402A JP2025525098A5 JP 2025525098 A5 JP2025525098 A5 JP 2025525098A5 JP 2025505402 A JP2025505402 A JP 2025505402A JP 2025505402 A JP2025505402 A JP 2025505402A JP 2025525098 A5 JP2025525098 A5 JP 2025525098A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutical composition
formula
salt
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025505402A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025525098A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/071141 external-priority patent/WO2024023360A1/en
Publication of JP2025525098A publication Critical patent/JP2025525098A/ja
Publication of JP2025525098A5 publication Critical patent/JP2025525098A5/ja
Pending legal-status Critical Current

Links

JP2025505402A 2022-07-29 2023-07-31 Ｉｐ５置換化合物 Pending JP2025525098A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22382737 2022-07-29
EP22382737.9 2022-07-29
PCT/EP2023/071141 WO2024023360A1 (en) 2022-07-29 2023-07-31 Ip5 substituted compounds

Publications (2)

Publication Number Publication Date
JP2025525098A JP2025525098A (ja) 2025-08-01
JP2025525098A5 true JP2025525098A5 (enExample) 2026-05-12

Family

ID=83319363

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025505402A Pending JP2025525098A (ja) 2022-07-29 2023-07-31 Ｉｐ５置換化合物

Country Status (11)

Country Link
EP (1) EP4562019A1 (enExample)
JP (1) JP2025525098A (enExample)
KR (1) KR20250049546A (enExample)
CN (1) CN119630679A (enExample)
AR (1) AR130072A1 (enExample)
AU (1) AU2023313051A1 (enExample)
CA (1) CA3263493A1 (enExample)
IL (1) IL318651A (enExample)
MX (1) MX2025001128A (enExample)
TW (1) TW202412815A (enExample)
WO (1) WO2024023360A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025162971A1 (en) * 2024-01-31 2025-08-07 Sanifit Therapeutics, S.A. Substituted ip5 compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
CA2132012C (en) 1992-03-25 2003-04-22 John W. Shell Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
ATE302597T1 (de) 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
NZ518739A (en) 1999-11-02 2004-12-24 Depomed Inc Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
MXPA02007254A (es) 2000-02-04 2002-12-09 Depomed Inc Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero.
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
WO2002096404A1 (en) 2001-05-29 2002-12-05 Depomed Development Ltd Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
ES2232302B1 (es) 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
US7741506B2 (en) 2005-04-26 2010-06-22 Berry & Associates, Inc. Probe for measuring phytase activity
US20060241308A1 (en) * 2005-04-26 2006-10-26 Berry & Associates, Inc. Probe for measuring phytase activity
ES2288126B2 (es) 2006-06-01 2009-07-06 Universitat De Les Illes Balears Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis.
ES2332636B1 (es) 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.
US8987514B2 (en) * 2009-02-04 2015-03-24 President And Fellows Of Harvard College Compositions and methods for labeling and imaging phospholipids
GB0920985D0 (en) 2009-11-30 2010-01-13 Queen Mary & Westfield College Novel inositol phosphate derivatives
EP2579036A1 (en) 2011-10-06 2013-04-10 Laboratorios Sanifit, S.L. Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200
SMT202100406T1 (it) 2015-12-11 2021-09-14 Eth Zuerich Derivati di inositolo per l'uso nella cristallizzazione patologica
EP3852767B1 (en) 2018-09-18 2025-12-17 Vifor (International) AG Calcium oxalate crystallization inhibitors for renal disorders
WO2021219135A1 (zh) 2020-04-30 2021-11-04 上海森辉医药有限公司 一种肌醇衍生物及其用途
EP4036097A1 (en) * 2021-01-29 2022-08-03 Sanifit Therapeutics S.A. Ip4-4,6 substituted derivative compounds

Similar Documents

Publication Publication Date Title
JP2025524914A5 (enExample)
JP2024504257A5 (enExample)
JP2024050527A5 (enExample)
RU2002101723A (ru) Инданилзамещенные бензолкарбонамиды, способ их получения, их применение в качестве лекарственного средства, а также содержащие их фармацевтические композиции
JP2007191486A5 (enExample)
RU2350605C2 (ru) Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ
JP2022522694A5 (enExample)
EA023500B1 (ru) Соединения, композиции и способы их применения для коррекции уровня мочевой кислоты
RU2011127079A (ru) Комбинация производного циклоспорина и нуклеозидов для лечения инфекции вирусом гепатита с
JP2019529444A5 (enExample)
RU2007116858A (ru) Тиазолилдигидроиндазолы
JP2018502891A5 (enExample)
KR101986272B1 (ko) 삼환식 화합물, 이를 포함하는 조성물 및 그의 용도
JP2025505200A5 (enExample)
RU2007101653A (ru) Производные 1-азабицикло[3.3.1]нонанов
JP2022541545A5 (enExample)
JP2022137237A5 (enExample)
JP2022537140A5 (enExample)
RU2005132168A (ru) Биарилзамещенные триазолы как блокаторы натриевых каналов
KR20180088411A (ko) 병적인 결정화에서의 용도를 위한 이노시톨 유도체
JP2018172383A5 (ja) 魚介類のベコ病の経口投与用治療剤組成物及びそれを用いた魚介類のベコ病の治療方法
JP2025508971A5 (enExample)
JP2024534420A5 (enExample)
JP2022536043A5 (enExample)
JP2021510168A5 (enExample)